Millions of Americans are struggling with addiction.1 reSET® and reSET-O® can help more of them access and remain in treatment.2-4*

*During 12 weeks of treatment.

THE CHALLENGE

SUD and OUD continue to impact our communities, but not enough people are receiving treatment1

Chart: 41.1 million Americans living with substance use disorder (SUD); 6.5% received formal SUD treatment Chart: 2.5 million Americans living with opioid use disorder (OUD); 11.2% received medication-assisted treatment in the past year
Chart: 41.1 million Americans living with substance use disorder (SUD); 6.5% received formal SUD treatment Chart: 2.5 million Americans living with opioid use disorder (OUD); 11.2% received medication-assisted treatment in the past year

MAT includes buprenorphine, methadone, or naltrexone plus psychosocial support.5

depiction of patient using smartphone

WHAT ARE PDTs?

Prescription digital therapeutics (PDTs) are innovative treatments designed for the way people live today

checkmark icon

FDA-authorized

checkmark icon

Tested for safety and effectiveness in randomized clinical trials

checkmark icon

Prescribed by healthcare professionals

checkmark icon

Real-time insights into patient engagement and progress

smartphones with reSET and reSET-O apps

WHAT ARE reSET AND reSET-O?

reSET and reSET-O are first-of-their-kind, FDA-authorized PDTs

  • Evidence-based treatment for SUD and OUD accessible on a smartphone2,4

  • Cognitive behavioral therapy lessons, fluency training to help patients remember what they’ve learned, and contingency management to earn rewards2,4‡

The rewards earned may be virtual (nonmonetary) or in the form of gift cards at the discretion of the prescriber.

WHY reSET AND reSET-O?

Bringing evidence-based treatment, data, and support
24/7 in an engaging PDT

smartphones with reSET and reSET-O apps

Patient-facing
PDT

Pear.MD Clinician dashboard on a laptop

Clinician
dashboard

image portraying of real-time patient data

Real-time
patient data

patient service center graphic

Fully digital,
end-to-end support

reSET® Indications for Use:

reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is indicated as a 12-week (90 day) prescription-only treatment for patients with substance use disorder (SUD), who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse.

It is intended to:

  • increase abstinence from a patient’s substances of abuse during treatment, and
  • increase retention in the outpatient treatment program.

reSET® Important Safety Information for Clinicians:

Warnings: reSET is intended for patients whose primary language is English with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET is not intended to be used as a stand-alone therapy for substance use disorder (SUD). reSET does not replace care by a licensed medical practitioner and is not intended to reduce the amount of face-to-face clinician time. reSET does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.

Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with substance use disorder also have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should engage in their normal care practices to monitor patients for medical problems and mental health disorders, including risk for harming others and/or themselves.

The long-term benefit of treatment with reSET on abstinence has not been evaluated in studies lasting beyond 12 weeks (90 days) in the SUD population. The ability of reSET to prevent potential relapse after treatment discontinuation has not been studied.

The effectiveness of reSET has not been demonstrated in patients currently reporting opioids as their primary substance of abuse.

Please see the Clinician Brief Summary Instructions for reSET.

reSET-O® Indications for Use:

reSET-O prescription digital therapeutic is a 12-week (84 day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

reSET-O® Important Safety Information for Clinicians:

Warnings/precautions: reSET-O is intended for patients whose primary language is English with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET-O is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET-O to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET-O to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner and is not intended to reduce the frequency or duration of in-person therapy. reSET-O does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.

Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should undertake standard of care to monitor patients for medical problems and mental health disease, including risk for harming others and/or themselves.

The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.

Please see the Clinician Brief Summary Instructions for reSET-O.